Neurocrine Provides Update on FDA Advisory Committee for INGREZZA™ (valbenazine) for the Treatment of Tardive Dyskinesia
The NDA for INGREZZA includes the results from the Kinect 2 and Kinect 3 clinical trials along with the results from another 18 clinical trials; extensive preclinical testing and drug manufacturing data were included in the NDA submission. The
Conference Call and Webcast at
Neurocrine will host a live conference call and webcast to discuss this press release on
If you are unable to attend the webcast a replay of the conference call will be available approximately one hour after the conclusion of the call by dialing 800-839-1229 (US) or 402-220-0459 (International) using the conference ID: NBIX. The call will be archived for one month.
About Tardive Dyskinesia
Tardive dyskinesia is characterized by involuntary, repetitive movements of the face, trunk, or extremities, including lip smacking, grimacing, tongue protrusion, facial movements or blinking, puckering and pursing of the lips. These symptoms are rarely reversible and there are currently no
VMAT2 is a protein concentrated in the human brain that is primarily responsible for re-packaging and transporting monoamines (dopamine, norepinephrine, serotonin, and histamine) in pre-synaptic neurons. INGREZZA (valbenazine or NBI-98854), developed in the Neurocrine laboratories, is a novel, highly-selective VMAT2 inhibitor that modulates dopamine release during nerve communication, showing little or no affinity for VMAT1, other receptors, transporters and ion channels. INGREZZA is designed to provide low, sustained, plasma and brain concentrations of active drug to allow for once daily dosing. The proprietary name INGREZZA has been conditionally accepted by the
Modulation of neuronal dopamine levels in diseases such as tardive dyskinesia, Tourette syndrome, Huntington's chorea, schizophrenia, and tardive dystonia, which are characterized, in part, by a hyperdopaminergic state, may provide symptomatic benefits for patients with these diseases.
The Company is also investigating the safety and efficacy of INGREZZA in the treatment of Tourette syndrome. The Company has two ongoing placebo-controlled Phase II Tourette syndrome studies evaluating INGREZZA in adults and pediatrics, the T-Forward study and T-Force GREEN study, respectively. Each of these studies is expected to enroll up to 90 subjects with Tourette syndrome. Additionally, the Company has recently launched an open-label, fixed-dose rollover study of INGREZZA in up to 180 subjects with Tourette syndrome.
In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with Neurocrine's business and finances in general, as well as risks and uncertainties associated with INGREZZA development. Specifically, the risks and uncertainties the Company faces include risks that the INGREZZA NDA may not obtain regulatory approval from the
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/neurocrine-provides-update-on-fda-advisory-committee-for-ingrezza-valbenazine-for-the-treatment-of-tardive-dyskinesia-300386655.html
Neurocrine Biosciences, Investor Relations, (858) 617-7600